Skip to main content
. Author manuscript; available in PMC: 2018 Feb 27.
Published in final edited form as: Cancer Res. 2017 Aug 30;77(21):5701–5705. doi: 10.1158/0008-5472.CAN-17-1510

Figure 1.

Figure 1

Signaling mechanisms and therapeutic targeting of SHP2 and PRLs. A, The schematic structure of SHP2, strategies of targeting SHP2 for cancer therapy, and the latest small-molecule SHP2 inhibitors. B, SHP2 promotes multiple oncogenic signaling pathways. C, PRL-mediated signaling in cancer. D, Strategies of targeting PRLs for cancer therapy and representative PRL inhibitors. EMT, epithelial–mesenchymal transition.